Sanofi pulls US lixisenatide filing
This article was originally published in Scrip
Sanofi has voluntarily withdrawn its approval filing in the US for lixisenatide, its GLP-1 receptor agonist for type 2 diabetes, which is already approved in Europe, Japan and elsewhere under the brand name Lyxumia.
You may also be interested in...
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.